A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
COPDCOPD Exacerbation
Trial Locations (1)

Unknown

Papanikolaou Hospital of Thessaloniki, Thessaloniki

Sponsors
All Listed Sponsors
lead

Elpen Pharmaceutical Co. Inc.

INDUSTRY